California's $3 billion stem cell research program is looking for a new president to carry the state agency through what may be the last three years of its life.
The search committee of the agency's 29-member governing board meets July 17 to discuss the matter behind closed doors. But members of the public will have a chance to comment during an open portion of the meeting. Or they can email comments directly to the board at info@cirm.ca.gov ahead of the meeting.
So far, no comments have been received from the public concerning the selection of a new president, according to an agency spokesman.
Currently Maria Millan is the interim president and CEO of the 12-year-old program, replacing Randy Mills, who is taking a job in Minneapolis. Mills has said that Millan is his choice as a successor. Millan joined the agency in December 2012 and was vice president for therapeutics before her interim appointment.
Last month, directors of the California Institute for Regenerative Medicine (CIRM), as the agency is formally known, ratified her as interim president, voicing no reservations in public about the action.
The current salary for the position ranges from $311,000 to $575,000 annually.
The main location for next week's session is the Claremont Hotel in Berkeley. Teleconference locations where the public make direct audio comments to the board are available in Sacramento and at UCLA in Los Angeles. Details are available on the agenda.
The agency has projected that it will run out of funds for new awards in June 2020. However, the end of funding could come sooner or later depending on the agency's rate of spending for awards. The agency relies on money borrowed by the state (bonds), which roughly doubles the cost of the research to about $6 billion because of interest costs.
Earlier, there was talk about a possible $5 billion bond election in 2018 to continue funding the agency. However, that possibility appears to have been delayed until November 2020, which would be beyond the date when the agency is currently expected to run out of cash.
Bob Klein, the Palo Alto real estatement investment banker who led the 2004 ballot campaign that created the stem cell agency, is the chief voice behind the idea of another bond issue. He has not responded to inquiries from the California Stem Cell Report about his latest bond plans. This blog will carry the full text of his comments if he does respond.
Here is a list of the members of the CIRM search group: Deborah Deas, Judy Gasson, David Higgins, Steve Juelsgaard, Al Rowlett, Jeff Sheehy, Jonathan Thomas, Art Torres and Kristiina Vuori. Biographical sketches can be found here.
Monday, July 10, 2017
Thursday, June 29, 2017
Alpha Thalassemia to Strokes to Zika: A $64 Million Boost by California for Stem Cell Research
BURLINGAME, Ca. -- The California stem cell agency today awarded more than $64 million for research tackling cancer, stroke, leukemia, heart failure, brain injury, Zika and much, much more
The funds went to Gary Steinberg of Stanford University.
Maria Millan, interim president and CEO of the agency, said in a news release,
The $12.1 million award (CLIN2-09183) went to Tippi MacKenzie of UC San Francisco. (The review summary can be found here.)
The fourth application (CLIN1-09776) involves acute myeloid leukemia and preparation for a clinical trial application. CIRM awarded $6.9 million to Cellerant Therapeutics, Inc., of San Carlos. The agency reported that $1.7 million in co-funding would be provided by Cellerant. (The review summary can be found here.)
Also approved was $20 million for 13 awards in what the agency calls its Quest program, which is aimed at supporting promising, less developed research that is likely to move on to the next stage of development within two years. Twenty-six applications were rejected.
The review summaries and scores on the awards can be found in this document. The list of recipients can be found in the CIRM press release.
The agency's directors allotted $44 million of the amount for two clinical trials and potentially two more trials, which are the last stages before approval of treatments for use by the general public. Prior to today's action, the agency -- known officially as the California Institute for Regenerative Medicine or CIRM -- was helping to finance 27 active clinical trials.
The agency has yet to develop therapies that would be available for widespread use that voters were led to expect in 2004 when they approved creation of the $3 billion research effort. CIRM expects to run out of cash for new awards in three years.
The agency has yet to develop therapies that would be available for widespread use that voters were led to expect in 2004 when they approved creation of the $3 billion research effort. CIRM expects to run out of cash for new awards in three years.
The most advanced clinical research approved today involves a phase 2b trial for which CIRM ponied up $20 million. The effort is also backed with co-funding of $22 million by the recipient, SanBio, Inc., a Mountain View, Ca., subsidiary of a Japanese firm, SanBio Co., Ltd.
The review summary of the application (CLIN2-10344) said the trial had already demonstrated safety and "a trend toward efficacy" involving ischemic strokes. The research is aimed at improving motor function of victims of strokes, which is the leading cause of adult disability.
Directors also approved $5.3 million for work aimed at starting a clinical trial for a treatment that would enhance the brain's ability to create new blood vessels to replace those damaged during a stroke. (The review summary for CLIN-09433 can be found here.)
The funds went to Gary Steinberg of Stanford University.
Maria Millan, interim president and CEO of the agency, said in a news release,
"Today the CIRM Board approved two very different methods, using different kinds of stem cells, to address this need. By funding 'multiple shots on goal' we believe that we have a better chance of finding a way to repair the damage caused by stroke and give people a better quality of life.”The second phase 2 clinical trial backed by CIRM involves transplantation of maternal bone marrow stem cells into fetuses discovered to have alpha thalassemia major, an affliction that is almost always fatal in utero.
The $12.1 million award (CLIN2-09183) went to Tippi MacKenzie of UC San Francisco. (The review summary can be found here.)
The fourth application (CLIN1-09776) involves acute myeloid leukemia and preparation for a clinical trial application. CIRM awarded $6.9 million to Cellerant Therapeutics, Inc., of San Carlos. The agency reported that $1.7 million in co-funding would be provided by Cellerant. (The review summary can be found here.)
Also approved was $20 million for 13 awards in what the agency calls its Quest program, which is aimed at supporting promising, less developed research that is likely to move on to the next stage of development within two years. Twenty-six applications were rejected.
The review summaries and scores on the awards can be found in this document. The list of recipients can be found in the CIRM press release.
Plans Scrubbed for a 2018 Bond Measure for California Stem Cell Research
BURLINGAME, Ca. -- Plans to ask California voters in 2018 to approve a $5 billion bond issue to finance the California stem cell agency have been shelved, a director of the agency said today.
Jeff Sheehy, a San Francisco county supervisor, said that the key backer of the proposal had informed him that no bond measure would be offered to voters before 2020, presumably at the presidential general election.
At a meeting of stem agency directors, Sheehy said this morning that Bob Klein, who led the 2004 ballot campaign that created the agency, had told him by telephone that a 2018 bond measure was now off the table.
Sheehy did not go into reasons for the delaying the bond measure. However, conventional political wisdom holds that bond measures have a better chance of approval during a general election that attracts a larger voter turnout.
J.T. Thomas, chairman of the agency's board, said he was forming a transition committee to make plans for various alternatives, including shutting down the agency in 2020. The California Institute for Regenerative (CIRM), as the agency is formally known, currently estimates that it will run out of cash for new awards in just three years.
Other alternatives to be examined include funding from a new bond measure and some sort of private-public partnership.
Jeff Sheehy, a San Francisco county supervisor, said that the key backer of the proposal had informed him that no bond measure would be offered to voters before 2020, presumably at the presidential general election.
At a meeting of stem agency directors, Sheehy said this morning that Bob Klein, who led the 2004 ballot campaign that created the agency, had told him by telephone that a 2018 bond measure was now off the table.
Sheehy did not go into reasons for the delaying the bond measure. However, conventional political wisdom holds that bond measures have a better chance of approval during a general election that attracts a larger voter turnout.
J.T. Thomas, chairman of the agency's board, said he was forming a transition committee to make plans for various alternatives, including shutting down the agency in 2020. The California Institute for Regenerative (CIRM), as the agency is formally known, currently estimates that it will run out of cash for new awards in just three years.
Other alternatives to be examined include funding from a new bond measure and some sort of private-public partnership.
CIRM Directors Open Morning Meeting
BURLINGAME, Ca. -- Directors of the $3 billion California stem cell agency opened their meeting this morning at 9:06 a.m. with introduction of the newest member of the board, Linda Malkas of the City of Hope, and a report from Chairman Jon Thomas.
Conflict List for CIRM Directors Clinical and Preclinical Awards
Here is the conflict of interest list for directors of the California stem cell agency compiled by the agency in preparation for voting today on applications for clinical and preclinical awards. The list identifies the directors with conflicts on specific applications. The directors with conflicts are barred from voting on those applications or discussing them during today's meeting.
Conflict List for CIRM Directors on Quest Awards
Here is the conflict of interest list for directors of the California stem cell agency compiled by the agency in preparation for voting today on applications for Quest research awards. The list identifies the directors with conflicts on specific applications. The directors with conflicts are barred from voting on those applications or discussing them during today's meeting.
Wednesday, June 28, 2017
Check Out All the Breaking California Stem Cell News Tomorrow -- Right Here on This Web Site
The California Stem Cell Report will bring you on-site, gavel-to-gavel coverage of tomorrow's meeting of the governing board of the Golden State's $3 billion stem cell agency.
The board is slated to approve $64 million in new awards for research into afflictions ranging from strokes to liver disease. Also to be approved is the appointment of Maria Millan as the interim president of the stem cell program. The excitement is scheduled to begin at 9 a.m. PDT.
For those who prefer to monitor online the nearly day-long meeting themselves, instructions can be found on the agenda. If you would like to attend, the meeting is in Burlingame at the San Francisco Airport Marriott Hotel. Two other public, telephonic locations can be found in Los Angeles and one each in Beverly Hills, Sacramento and La Jolla.
Specific addresses and more information can be found on the agenda.
The board is slated to approve $64 million in new awards for research into afflictions ranging from strokes to liver disease. Also to be approved is the appointment of Maria Millan as the interim president of the stem cell program. The excitement is scheduled to begin at 9 a.m. PDT.
For those who prefer to monitor online the nearly day-long meeting themselves, instructions can be found on the agenda. If you would like to attend, the meeting is in Burlingame at the San Francisco Airport Marriott Hotel. Two other public, telephonic locations can be found in Los Angeles and one each in Beverly Hills, Sacramento and La Jolla.
Specific addresses and more information can be found on the agenda.
Tuesday, June 27, 2017
Seeking a CEO: $3 Billion California Stem Cell Agency Faces Critical Leadership Challenges
California's 12-year-old stem cell research effort is expected to give away tens of millions of dollars in public this week, but its most important matters -- issues that deal with its survival and future -- likely will be discussed behind closed doors at a meeting Thursday of its governing board
On the table is the leadership of the $3 billion organization, which is scheduled to run out of cash in just three years, which amounts to a mere tick of the clock in the world of biomedical research. Beginning next week the California Institute for Regenerative Medicine (CIRM), as the agency is formally known, will be minus its chief executive officer and its longtime counselor, who even predates the organization's actual creation in 2004.
CIRM directors are scheduled to meet Thursday at the San Francisco Marriott hotel in Burlingame, Ca., to confirm the appointment of Maria Millan, CIRM's vice president of therapeutics, as interim president of the agency. She will assume the duties of Randy Mills, who is leaving CIRM next week to head the National Marrow Donor Progam.
Mills, who was paid $573,00 last year, also made it clear to the California Stem Cell Report in May that Millan is the appropriate person to take over the agency on a permanent basis after he leaves.
However, the decision is up to the 29-member board, which has scheduled an executive session Thursday to discuss the interim replacement for Mills. He joined the agency only three years ago but has left an impressive mark.
CIRM directors have also scheduled a July 17 meeting of their presidential search subcommittee to deal with the agency's leadership during what could be the last years of its life.
CIRM has a checkered record in recruiting new presidents for a variety of reasons (see here, here and here). Some candidates have rejected offers. Other search efforts have been excessively prolonged.
Finding a new president from outside CIRM poses difficulties that would not have been in place, for example, five years ago. They include the tenuous future of CIRM along with the time needed for a normal executive search, plus the learning curve for a new CEO.
While CIRM is a small enterprise in some ways (less than 50 employees), it is an unusual mix of government, biotech business and academia, unlike any other state agency. The combination has raised hurdles in the past.
The clock is running out fast at the agency. Any alterations in the plan put in place by Mills, Millan and company could slow its efforts to fulfill voter expectations that the agency would actually generate a widely available therapy. CIRM is helping to finance 27 current clinical trials, which are the last stages in research prior to a product reaching the market. The agency hopes to add 38 more trials over the next three years. But there are no guarantees that any will be successful.
Millan can step in and pick up the job relatively seamlessly. Bringing in a CEO from outside could well take six months or more, including relocation. But serving as the head of an organization that could be out of business in three years may not be appealing to many and could prolong recruitment.
If Millan is bypassed by the board, she may well leave the agency, triggering a cascade of departures as other CIRM employees also look to their own professional futures. An employee drain would hamper the agency's drive to come up with a commercial therapy.
James Harrison, the longtime counsel to the agency, is also leaving at the end of this week, returning to other pursuits at his private practice. Harrison has been a cornerstone of CIRM and has influence well beyond the not-so-simple legal matters involving the agency. He was also one of the authors of the 10,000-word ballot initiative that created the agency in 2004.
Scott Tocher, a longtime veteran of the agency, will replace Harrison. An announcement of the appointment is expected at the Thursday meeting.
Looming in the background is a gossamer plan for another ballot initiative to fund CIRM beyond 2020. Bob Klein, a Palo Alto real estate investment banker who led the campaign that created CIRM, is talking about a $5 billion bond measure on the ballot as early as November of next year. Some political observers have predicted a less-than-warm-reception for such a proposal, given that the agency has yet to measure up to its 2004 campaign promises.
Another, rival proposal is being mentioned that would, in fact, move stem cell funding away from the agency.
One stem cell scientist, Paul Knoepfler of UC Davis, wrote last week about the agency's presidential search.
Commenting on his blog, Knoepfler said that CIRM directors should pick a "fantastic" person to replace Mills. Knoepfler said the new president should have "strong leadership skills," a "big picture clinical vision" and "impeccable stem cell credentials," criteria that one could argue have not been met by most CIRM CEOs.
In the past, debate about presidential candidates centered on whether they should be stem cell stars or a leader who can execute an aggressive program that is already approved and in place. Given the current CIRM challenges, other criteria, such as speed and continuity, are also high.
The journal Nature this year said that the agency is in its "last stage." CIRM directors may well have that admonition on their minds as they consider fresh leadership for the program.
On the table is the leadership of the $3 billion organization, which is scheduled to run out of cash in just three years, which amounts to a mere tick of the clock in the world of biomedical research. Beginning next week the California Institute for Regenerative Medicine (CIRM), as the agency is formally known, will be minus its chief executive officer and its longtime counselor, who even predates the organization's actual creation in 2004.
CIRM directors are scheduled to meet Thursday at the San Francisco Marriott hotel in Burlingame, Ca., to confirm the appointment of Maria Millan, CIRM's vice president of therapeutics, as interim president of the agency. She will assume the duties of Randy Mills, who is leaving CIRM next week to head the National Marrow Donor Progam.
Mills, who was paid $573,00 last year, also made it clear to the California Stem Cell Report in May that Millan is the appropriate person to take over the agency on a permanent basis after he leaves.
However, the decision is up to the 29-member board, which has scheduled an executive session Thursday to discuss the interim replacement for Mills. He joined the agency only three years ago but has left an impressive mark.
CIRM directors have also scheduled a July 17 meeting of their presidential search subcommittee to deal with the agency's leadership during what could be the last years of its life.
CIRM has a checkered record in recruiting new presidents for a variety of reasons (see here, here and here). Some candidates have rejected offers. Other search efforts have been excessively prolonged.
Finding a new president from outside CIRM poses difficulties that would not have been in place, for example, five years ago. They include the tenuous future of CIRM along with the time needed for a normal executive search, plus the learning curve for a new CEO.
While CIRM is a small enterprise in some ways (less than 50 employees), it is an unusual mix of government, biotech business and academia, unlike any other state agency. The combination has raised hurdles in the past.
The clock is running out fast at the agency. Any alterations in the plan put in place by Mills, Millan and company could slow its efforts to fulfill voter expectations that the agency would actually generate a widely available therapy. CIRM is helping to finance 27 current clinical trials, which are the last stages in research prior to a product reaching the market. The agency hopes to add 38 more trials over the next three years. But there are no guarantees that any will be successful.
Millan can step in and pick up the job relatively seamlessly. Bringing in a CEO from outside could well take six months or more, including relocation. But serving as the head of an organization that could be out of business in three years may not be appealing to many and could prolong recruitment.
If Millan is bypassed by the board, she may well leave the agency, triggering a cascade of departures as other CIRM employees also look to their own professional futures. An employee drain would hamper the agency's drive to come up with a commercial therapy.
James Harrison, the longtime counsel to the agency, is also leaving at the end of this week, returning to other pursuits at his private practice. Harrison has been a cornerstone of CIRM and has influence well beyond the not-so-simple legal matters involving the agency. He was also one of the authors of the 10,000-word ballot initiative that created the agency in 2004.
Scott Tocher, a longtime veteran of the agency, will replace Harrison. An announcement of the appointment is expected at the Thursday meeting.
Looming in the background is a gossamer plan for another ballot initiative to fund CIRM beyond 2020. Bob Klein, a Palo Alto real estate investment banker who led the campaign that created CIRM, is talking about a $5 billion bond measure on the ballot as early as November of next year. Some political observers have predicted a less-than-warm-reception for such a proposal, given that the agency has yet to measure up to its 2004 campaign promises.
Another, rival proposal is being mentioned that would, in fact, move stem cell funding away from the agency.
One stem cell scientist, Paul Knoepfler of UC Davis, wrote last week about the agency's presidential search.
Commenting on his blog, Knoepfler said that CIRM directors should pick a "fantastic" person to replace Mills. Knoepfler said the new president should have "strong leadership skills," a "big picture clinical vision" and "impeccable stem cell credentials," criteria that one could argue have not been met by most CIRM CEOs.
In the past, debate about presidential candidates centered on whether they should be stem cell stars or a leader who can execute an aggressive program that is already approved and in place. Given the current CIRM challenges, other criteria, such as speed and continuity, are also high.
The journal Nature this year said that the agency is in its "last stage." CIRM directors may well have that admonition on their minds as they consider fresh leadership for the program.
Thursday, June 15, 2017
Guest Posting: "Stem Cell Options Should be on the Table"
(Editor's note: The following is a guest posting from Joseph Rodota and Bernard Munos, both of whom have been active in California policy matters for some time. More biographical information can be found at the end of the item. The California Stem Cell Report welcomes diverse, well-considered views on California stem cell issues. If you have something that you think should see the light of day, please send it to djensen@californiastemcellreport.com.)
By Joseph Rodota and Bernard Munos
The sponsors of Proposition 71, the 2004 initiative that provided $3 billion in bonds to support stem-cell research, are readying a proposal to keep the agency alive after the last of these funds have been given out. According to recent news reports, a new $5 billion bond could be on the California ballot as early as November 2018.
Researchers supported by the California Institute for Regenerative Medicine (CIRM) have published hundreds of academic articles, but placed fewer than 30 drugs in clinical trials.
Even if all of these clinical trials resulted in drug candidates, they would still come up against the so-called “Valley of Death”—the well-documented shortage of funding for early-stage translational research.
California needs to move regenerative medicine from an academic timeline to a business timeline. The skills needed to turn an academic discovery into a commercial product are very different from the skills needed to be a successful academic scientist.
We proposed an alternative to continuing the current approach -- a state bond with three distinctive features:
A Focus on Entrepreneurs: Funds would be available only to companies, not academics (who would still be able to tap into billions in NIH funding for stem cell research);
A Focus on California: Only companies with a headquarters and a majority of employees in California, the nation’s center of overall innovation, or willing to relocate here; and
A Focus on Breakthrough Medicine: Only companies working on projects that have the potential to greatly impact patient health would qualify.
The University of California is well-qualified to administer this bond and report on its operations to the Legislature and the Governor, without the need for the cumbersome and controversial governance structure put in place by Proposition 71.
In exchange for the funds they receive, companies would tender to the University of California shares of their common stock, with an estimated value as determined by the most recent outside valuation or price set by investors. These shares would become part of the UC endowment -- and the University of California be free to sell or leverage these shares, or acquire additional shares, as it sees fit.
CIRM has over-invested in academic research, and under-invested in translating that research into therapies that cure diseases and prolong heathy lives. California needs to right that balance.
(Joe Rodota served as Cabinet Secretary to former California Governor Pete Wilson and director of policy for Arnold Schwarzenegger’s 2003 recall campaign. Munos is a senior fellow with FasterCures and the founder of the Innothink Center for Research in Biomedical Innovation.).
Here is a summary of the bond proposal.
By Joseph Rodota and Bernard Munos
The sponsors of Proposition 71, the 2004 initiative that provided $3 billion in bonds to support stem-cell research, are readying a proposal to keep the agency alive after the last of these funds have been given out. According to recent news reports, a new $5 billion bond could be on the California ballot as early as November 2018.
Researchers supported by the California Institute for Regenerative Medicine (CIRM) have published hundreds of academic articles, but placed fewer than 30 drugs in clinical trials.
Even if all of these clinical trials resulted in drug candidates, they would still come up against the so-called “Valley of Death”—the well-documented shortage of funding for early-stage translational research.
California needs to move regenerative medicine from an academic timeline to a business timeline. The skills needed to turn an academic discovery into a commercial product are very different from the skills needed to be a successful academic scientist.
We proposed an alternative to continuing the current approach -- a state bond with three distinctive features:
A Focus on Entrepreneurs: Funds would be available only to companies, not academics (who would still be able to tap into billions in NIH funding for stem cell research);
A Focus on California: Only companies with a headquarters and a majority of employees in California, the nation’s center of overall innovation, or willing to relocate here; and
A Focus on Breakthrough Medicine: Only companies working on projects that have the potential to greatly impact patient health would qualify.
The University of California is well-qualified to administer this bond and report on its operations to the Legislature and the Governor, without the need for the cumbersome and controversial governance structure put in place by Proposition 71.
In exchange for the funds they receive, companies would tender to the University of California shares of their common stock, with an estimated value as determined by the most recent outside valuation or price set by investors. These shares would become part of the UC endowment -- and the University of California be free to sell or leverage these shares, or acquire additional shares, as it sees fit.
CIRM has over-invested in academic research, and under-invested in translating that research into therapies that cure diseases and prolong heathy lives. California needs to right that balance.
(Joe Rodota served as Cabinet Secretary to former California Governor Pete Wilson and director of policy for Arnold Schwarzenegger’s 2003 recall campaign. Munos is a senior fellow with FasterCures and the founder of the Innothink Center for Research in Biomedical Innovation.).
Here is a summary of the bond proposal.
SUMMARY -- California Next Generation Cures Bond -- June 2017 uploaded by DavidJensen on Scribd
Tuesday, June 13, 2017
California Stem Cell Agency Reports 'Streak of Good News' on Asterias Spinal Therapy
Asterias video
California's $3 billion stem cell program today reported ongoing rosy results in a clinical trial involving a therapy for severe spinal cord injury.The treatment is being developed Asterias Biotherapeutics, Inc., of Fremont, Ca., with $14.3 million from the state research program, which is now in its 12th year.
The latest news was reported on The Stem Cellar, the agency's blog, and was based on a news release from Asterias, which is publicly traded.
Todd Dubnicoff, the agency's multimedia editor, wrote the item which discussed nine-month results for the trial involving six patients paralyzed from the neck down. He said,
"In a nut shell, their improvements in arm, hand and finger movement seen at the earlier time points have persisted and even gotten better at 9 months."Dubnicoff said that the level of improvement "can mean the difference between needing 24-hour a day home care versus dressing, feeding and bathing themselves."
He said,
"The impact of this level of improvement cannot be overstated. As mentioned in the press release, regaining these abilities, 'can result in lower healthcare costs, significant improvements in quality of life, increased ability to engage in activities of daily living, and increased independence.'"In the Asterias press release, Edward Wirth, chief medical officer for the company, said,
“The new efficacy results show that previously reported meaningful improvements in arm, hand and finger function in the 10 million cell cohort treated with AST-OPC1 cells have been maintained and in some patients have been further enhanced even 9 months following dosing. We are increasingly encouraged by these continued positive results, which are remarkable compared with spontaneous recovery rates observed in a closely matched untreated patient population.”The company also reported that no "serious adverse events" have surfaced that could be attributed to the therapy, which was initially developed by Geron, Inc., which received $6.4 million from the stem cell agency. Geron abandoned the trial for financial reasons, and Asterias acquired the technology.
Aserias' stock price jumped nearly 13 percent today, hitting $3.55. Its 52 week high is $5.80 and its 52-week low is $2.30.
Saturday, May 27, 2017
California Stem Cell Report Going Dark for a Few Days
The California Stem Cell Report expects to be offline for perhaps the next five to seven days.
The moving home of this web site, the sailing vessel Hopalong, will be making a passage north from Mazatlan into the Sea of Cortez, formally known as the Gulf of California. We will not have access to cellular or Internet coverage during that time.
The moving home of this web site, the sailing vessel Hopalong, will be making a passage north from Mazatlan into the Sea of Cortez, formally known as the Gulf of California. We will not have access to cellular or Internet coverage during that time.
A Longer Look at the Golden State's Stem Cell Research Efforts
Here is the overview of the California stem cell agency, published May 23, 2017, on Capitol Weekly and written by yours truly.
Friday, May 26, 2017
California's 'Great Ideas,' Stem Cell Awards Target Universal Blood Supply, Alzheimer's and Much More
The California stem cell agency this week awarded a total of $1.4 million to six scientists to jump start their work in what it calls its "great ideas" program.
The awards went for research ranging from creation of a universal blood supply with human stem cells to mitigating Alzheimer's disease, which has seen an increase of 55 percent in its death rate from 1999 to 2014, according to results of a new study released yesterday
The agency said in a press release that the "Inception" program "provides seed funding for great ideas that have the potential to impact human stem cell research, but need some initial support. It’s hoped this will enable the researchers to test their ideas, and give them the data they need to compete for more substantial funding."
Jonathan Thomas, chairman of the agency's governing board, said,
The blood supply award was a reminder of another program that the agency used to entice star researchers to California. The blood grant went to Tannishtha Reya of UC San Diego. She came to California with her spouse, Robert Wechsler-Reya. He was lured by CIRM in 2010 with $5 million in funding to work at the Sanford-Burnham Medical Research Institute in La Jolla.. He has not received any further funding from the agency. This is the first CIRM award for Reya.
Another round of the Inception program is scheduled to open up in January 2018. Here is a link to the most recent request for applications.
Here is a list of the winners with their application numbers. The summaries of reviewer comments on each application and their scores can be found here. All of the institutions have ties to CIRM board members, who are not permitted to vote on applications involving their institutions. However, they can vote on creation of the research grant programs, establishment of their scope and rules.
The awards went for research ranging from creation of a universal blood supply with human stem cells to mitigating Alzheimer's disease, which has seen an increase of 55 percent in its death rate from 1999 to 2014, according to results of a new study released yesterday
The agency said in a press release that the "Inception" program "provides seed funding for great ideas that have the potential to impact human stem cell research, but need some initial support. It’s hoped this will enable the researchers to test their ideas, and give them the data they need to compete for more substantial funding."
Jonathan Thomas, chairman of the agency's governing board, said,
"This is a high risk, high reward program. We feel that a small investment now could produce enormous benefits later.”The funding is small indeed. The California Institute for Regenerative Medicine(CIRM), as the agency is formally known, finances some clinical trials at $20 million a crack. The largest award in the "great ideas" program was $265,500.
The blood supply award was a reminder of another program that the agency used to entice star researchers to California. The blood grant went to Tannishtha Reya of UC San Diego. She came to California with her spouse, Robert Wechsler-Reya. He was lured by CIRM in 2010 with $5 million in funding to work at the Sanford-Burnham Medical Research Institute in La Jolla.. He has not received any further funding from the agency. This is the first CIRM award for Reya.
Another round of the Inception program is scheduled to open up in January 2018. Here is a link to the most recent request for applications.
Here is a list of the winners with their application numbers. The summaries of reviewer comments on each application and their scores can be found here. All of the institutions have ties to CIRM board members, who are not permitted to vote on applications involving their institutions. However, they can vote on creation of the research grant programs, establishment of their scope and rules.
| DISC1-10074 | Reprogramming human stem cells for blood cell generation | T. Reya – U.C. San Diego | $232,200 |
| DISC1-10036 | Prodrug innovation to target muscle stem cells and enhance muscle regeneration | H. Blau – Stanford University | $235,834 |
| DISC1-10079 | An exosome-based translational strategy to mitigate Alzheimer’s disease neuropathology | J. Baulch – U.C. Irvine | $179,911 |
| DISC1-09912 | A novel tissue engineering technique to repair degenerated retina | B. Thomas – University of Southern California | $215,133 |
| DISC1-09999 | Generation of expandable, self-renewing muscle stem cells for Duchenne Muscular Dystrophy | A. Sacco – Sanford-Burnham Medical Research Institute Letter to board |
$265,500 |
| DISC1-09984 | Hypo-immunogenic cardiac patches for myocardial regeneration | S. Schrepfer – U.C. San Francisco Letter to board |
$238,500 |
Tuesday, May 23, 2017
A Look at the California Stem Cell Agency: Its Origins, Its Accomplishments and Its Future
The Capitol Weekly online news and information service this afternoon posted a major overview of the $3 billion California stem cell agency.
The piece covered the agency's origins, recent high water marks and discussed its future. Here is the beginning of the freelance article by yours truly.
The piece covered the agency's origins, recent high water marks and discussed its future. Here is the beginning of the freelance article by yours truly.
"C. Randal Mills, the 45-year-old CEO of California’s $3 billion stem cell research program, is a man who loves his milestones.
"A private pilot, he charts his course in the air from one specific point to the next. Three years ago, Mills brought that same sort of navigation to the state stem cell agency. Miss one of the agency’s milestones, and — if you’re a stem cell scientist — you may not crash and burn, but you could lose millions of dollars in research funding from the state.
"Mills has left an indelible stamp on the agency with his emphasis on concrete, measurable results. But he is resigning from the research program at the end of June in the midst of what some say is its “last stage.” His surprise departure to head the world’s largest bone marrow donor organization shocked many in California’s stem cell community. And it added to the unease about its future along with the future of possible stem cell therapies."(For those of you who read a brief item this morning about how this blog was going to go dark for a few days while it was on an ocean passage in the Sea of Cortez, we had a minor setback. Our floating home, the sailing vessel Hopalong, suffered a mechanical problem that we could not fix at sea, so we returned to port for repairs. The voyage begins anew tomorrow morning.)
Major Overview of California Stem Cell Upcoming This Afternoon
Look for a major overview of the $3 billion California stem cell agency later today on Capitol Weekly, a well-respected online news and information service that focuses on state government and politics.
The piece was written by yours truly on a freelance basis for Capitol Weekly and includes the latest developments at the agency, including what departing president Randy Mills leaves behind.
Given the vagaries of the Internet and news, publication of the article cannot be totally guaranteed this afternoon. So if it doesn't pop up today, try again later this week.
Meanwhile, the California Stem Cell Report is going dark for a number of days while it makes an ocean voyage in its maritime home, the sailing vessel Hopalong, in the Sea of Cortez. Coverage of the agency is expected to resume perhaps by this weekend when an Internet connection can be found in Baja California.
The piece was written by yours truly on a freelance basis for Capitol Weekly and includes the latest developments at the agency, including what departing president Randy Mills leaves behind.
Given the vagaries of the Internet and news, publication of the article cannot be totally guaranteed this afternoon. So if it doesn't pop up today, try again later this week.
Meanwhile, the California Stem Cell Report is going dark for a number of days while it makes an ocean voyage in its maritime home, the sailing vessel Hopalong, in the Sea of Cortez. Coverage of the agency is expected to resume perhaps by this weekend when an Internet connection can be found in Baja California.
Monday, May 22, 2017
California Stem Cell Agency Has Opportunity for 'All-in" Executive Assistant
Looking for a great job with a $3 billion operation headquartered in downtown Oakland? You will be able to share in the progress of one of the hottest biomedical fields in the country and perhaps help save some lives.
The job is executive assistant to the president of the California stem cell agency. The current president, Randy Mills, is leaving at the end of June. Maria Millan, now vice president for therapeutics, is taking over as the interim CEO. She is line to succeed Mills, but there is no guarantee on that.
The job is no walk-in-the-park. The agency is small -- only 46 employees -- despite its reach. Long hours could be the order of the day.
The job posting on the agency's web site says the position requires an "all-in" commitment to the goals of the agency. Salary can range up to $10,433 a month.
The job is executive assistant to the president of the California stem cell agency. The current president, Randy Mills, is leaving at the end of June. Maria Millan, now vice president for therapeutics, is taking over as the interim CEO. She is line to succeed Mills, but there is no guarantee on that.
The job is no walk-in-the-park. The agency is small -- only 46 employees -- despite its reach. Long hours could be the order of the day.
The job posting on the agency's web site says the position requires an "all-in" commitment to the goals of the agency. Salary can range up to $10,433 a month.
Thursday, May 18, 2017
Bones, Stem Cells and Bridging the Gap
California's $3 billion stem cell research effort chalked up a small score yesterday with the announcement that a $5.2 million investment is making progress towards development of a therapy to regenerate broken bones.
Writing on the the state stem cell agency's blog, Karen Ring, social media manager for the agency, said,
"Scientists from Cedars-Sinai Medical Center have developed a new stem cell-based technology in animals that mends broken bones that can’t regenerate on their own. Their research was published today in the journal Science Translational Medicine and was funded in part by a CIRM Early Translational Award."The award went to Dan Gazit and Hyun Bae at Cedars. Their year one and two progress reports involving the adult stem cell therapy can be found at the link in the above paragraph.
Ring's blog item also carried a nifty graphic on the work and a link to a video on the research.
Ring wrote,
"Over two million bone grafts are conducted every year to treat bone fractures caused by accidents, trauma, cancer and disease. In cases where the fractures are small, bone can repair itself and heal the injury. In other cases, the fractures are too wide and grafts are required to replace the missing bone.
"It sounds simple, but the bone grafting procedure is far from it and can cause serious problems including graft failure and infection. People that opt to use their own bone (usually from their pelvis) to repair a bone injury can experience intense pain, prolonged recovery time and are at risk for nerve injury and bone instability."
Tuesday, May 16, 2017
Read All About It! Bad News for The Stem Cell 'Other'
It is a sad day for the stem cell "other."
Only 11 percent of the readers of one stem cell blog say they fit that category. That was a big drop from the early returns that showed the "other" with 21 percent.
(Never mind that we don't know the precise number of eyeballs actually represented by that 11 percent.)
All of this is the product of The Niche, the blog of UC Davis stem cell researcher Paul Knoepfler. He mounted a poll last week for readers to determine both their interests and general identity.
Initially "other" sprang into the lead. But as more readers responded, the reader category of academic scientists moved to the top with 32 percent. Industry scientists followed with 19 percent and patient or patient advocates with 17 percent.
What were they interested in? Investigations, 25 percent, newsy items, 20 percent, and journal club-like paper reviews, 18 percent. Less than four percent of readers identified themselves as interested laypersons.
If you are feeling left out, there is still time to respond by going to this link. A chance at free stem cell swag is being offered. And the swag is better than a used petri dish.
Only 11 percent of the readers of one stem cell blog say they fit that category. That was a big drop from the early returns that showed the "other" with 21 percent.
(Never mind that we don't know the precise number of eyeballs actually represented by that 11 percent.)
All of this is the product of The Niche, the blog of UC Davis stem cell researcher Paul Knoepfler. He mounted a poll last week for readers to determine both their interests and general identity.
Initially "other" sprang into the lead. But as more readers responded, the reader category of academic scientists moved to the top with 32 percent. Industry scientists followed with 19 percent and patient or patient advocates with 17 percent.
What were they interested in? Investigations, 25 percent, newsy items, 20 percent, and journal club-like paper reviews, 18 percent. Less than four percent of readers identified themselves as interested laypersons.
If you are feeling left out, there is still time to respond by going to this link. A chance at free stem cell swag is being offered. And the swag is better than a used petri dish.
Friday, May 12, 2017
$20 Million, California-backed Stem Cell Trial Discloses Disappointing News
Capricor's stock price plummeted 62 percent following what the company called the "unexpected" news, dropping from $1.89 to $1.16. California's stem cell agency has backed the trial with $20 million, plus an additional $7 million for earlier, related research.
The agency, formally known as the California Institute for Regenerative Medicine (CIRM), said on its blog,
"Obviously this is disappointing news for everyone involved, but we know that not all clinical trials are going to be successful. CIRM supported this research because it clearly addressed an unmet medical need and because an earlier Phase 1 study had showed promise in helping prevent decline in heart function after a heart attack."In response to a question, Kevin McCormack, senior director of communications, said the agency is talking to Capricor about the next steps. The agency regularly halts funding of awards when recipients do not meet milestones. McCormack did not respond to a question about how much money the firm had already received from CIRM.
Capricor, which is headquartered in Beverly Hills, said in a press release that an interim analysis on the phase two trial has "has demonstrated a low probability (futility) of achieving a statistically-significant difference in the 12-month primary efficacy endpoint." The company said there was "no notable difference" between treatment groups.
The company said it would cut its workforce to focus more sharply on its treatment of Duchenne muscular dystrophy, which the stem cell agency is also backing with $3.4 million. The Duchenne treatment had better news the last month, clearing its phase one trial with no adverse effects.
Timothy Henry and Rajenda Makkar of the Cedars-Sinai Heart Institute in Los Angeles are the principal investigators for the clinical trial.
The highest price for Capricor stock over the last 12 months was $5.40 and the lowest was $1.13.
Here are links to additional news stories today on Capricor: BiopharmaDive, MarketWatch, Genetic Engineering News,
Subscribe to:
Posts (Atom)